This article is more than 5 years old. Information may no longer be current.
7 stories you may have missed in August
Click Here to Manage Email Alerts
Healio Gastroenterology and Liver Disease has compiled a list of some of the top stories we reported in August.
Our readers were most interested in recent news on colorectal cancer, as well as a movement to change the way GIs talk about fecal microbiota transplant.
Oral antibiotics tied to colorectal cancer risk
Certain oral antibiotics are associated with increased risk for colon cancer, while others are linked with reduced rectal cancer risk, according to study results published in Gut.
Cynthia L. Sears, MD, of the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University School of Medicine, and colleagues wrote that several previous studies have shown an association between antibiotics and cancer, but they have not explored how that effect is impacted by antibiotic type or tumor location. READ MORE.
VIDEO: ‘Good, bad news’ for the future of colorectal cancer screening
In this exclusive video from GI Outlook 2019, T.R. Levin, MD, the chief of gastroenterology at Kaiser Permanente Medical Center, discusses the future of colorectal cancer screening and its viability in practice management.
“I think increasingly patients are going to ask for non-invasive screening instead of colonoscopy or using non-invasive screening to achieve much higher population rates of screening,” Levin told Healio Gastroenterology and Liver Disease. READ MORE.
Multiple FIT rounds offer better diagnostic yield for advanced neoplasia
Multiple rounds of fecal immunochemical tests sent to patients through the mail had a higher diagnostic yield for advanced neoplasia among invitees compared with one-time flexible sigmoidoscopy or one-time colonoscopy, according to study results.
Manon C.W. Spaander , MD, PhD, of the department of gastroenterology and hepatology at Erasmus University Medical Center in the Netherlands, and colleagues wrote that it is unclear which screening technique offers the largest effect on colorectal cancer morbidity and mortality. READ MORE.
Novel therapy shows potential for acid suppression
Tegoprazan, a novel therapy for GERD, was well-tolerated and showed rapid, dose-dependent acid suppression, according to results of a phase 1 study.
Kyun-Seop Bae, MD, PhD, of the department of clinical pharmacology and therapeutics at the University of Ulsan in South Korea, and colleagues wrote that tegoprazan (CJ HealthCare), is a potassium-competitive acid blocker (P-CAB) that works by reversibly suppressing gastric H+/K+ATPase. READ MORE.
Cleaning up an image: the crusade to rename fecal microbiota transplant
As more attention is directed toward FMT, there too has been an uptick in misrepresentations of the treatment that has notably increased people’s misconceptions.
As Alexander Khoruts, MD, medical director of the University of Minnesota Microbiota Therapeutics Program, notes, part of the problem lies with the language used to describe this treatment. People, including physicians and scientists, commonly forgo the word “microbiota” when talking about it and simply refer to it as “fecal transplant.” READ MORE.
Colorectal cancer on the rise among younger Canadians
A recent cohort study identified an increasing incidence of colorectal cancer diagnoses among Canadian men and women younger than 50 years.
“While rates among adults younger than 50 are still considerably lower than older adults, our results suggest that more recent birth cohorts are seeing the highest rates ever recorded in Canada,” Darren R. Brenner, PhD, of the University of Calgary, told Healio Gastroenterology and Liver Disease. “This is in contrast to adults where population-based screening programs are proving effective at reducing the incidence and subsequent mortality from colorectal cancer.” READ MORE
1 to 2 adenomas at baseline linked with lower advanced neoplasia risk
Colonoscopy findings at baseline screening are associated with advanced neoplasia within 10 years, and patients with just one or two adenomas at baseline are at lower risk, according to research published in Gastroenterology.
“Because surveillance exposes participants to the risks inherent to invasive procedures and higher resource utilization, further studies are needed investigating the outcomes of surveillance across various risk groups with different baseline colonoscopy findings in a true screening population,” Dawn Provenzale, MD, MS, director of the cooperative studies program epidemiology center at Durham Veterans Affairs Health Care Systems, and colleagues wrote. READ MORE